MENU
+Compare
AQST
Stock ticker: NASDAQ
AS OF
Nov 25, 02:51 PM (EDT)
Price
$5.89
Change
+$0.11 (+1.90%)
Capitalization
705.79M

AQST Aquestive Therapeutics Forecast, Technical & Fundamental Analysis

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs... Show more

AQST
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for AQST with price predictions
Nov 24, 2025

AQST in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 10, 2025

AQST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 36 cases where AQST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AQST's RSI Oscillator exited the oversold zone, of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where AQST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 24, 2025. You may want to consider a long position or call options on AQST as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for AQST turned negative on October 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

AQST moved below its 50-day moving average on November 10, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AQST crossed bearishly below the 50-day moving average on November 13, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AQST entered a downward trend on November 24, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (17.176). P/E Ratio (0.000) is within average values for comparable stocks, (72.389). AQST's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.933). AQST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (13.228) is also within normal values, averaging (56.095).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AQST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
AQST
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

AQST is expected to report earnings to fall 2.86% to -13 cents per share on March 10

Aquestive Therapeutics AQST Stock Earnings Reports
Q4'25
Est.
$-0.14
Q3'25
Est.
$-0.14
Q2'25
Beat
by $0.03
Q1'25
Missed
by $0.08
Q4'24
Missed
by $0.06
The last earnings report on November 05 showed earnings per share of -14 cents, meeting the estimate of -14 cents. With 937.19K shares outstanding, the current market capitalization sits at 705.79M.
A.I. Advisor
published General Information

General Information

a developer thin film pharmaceutical and over the counter drug products

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
30 Technology Drive
Phone
+1 908 941-1900
Employees
135
Web
https://www.aquestive.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CMGSX35.37N/A
N/A
BlackRock Mid-Cap Growth Equity Svc
ALSAX10.78N/A
N/A
Alger Small Cap Growth A
FIJYX42.63N/A
N/A
Fidelity Advisor Biotechnology Z
VTAIX10.94N/A
N/A
Virtus Tactical Allocation I
SUTCX3.78N/A
N/A
AB Sustainable US Thematic C

AQST and Stocks

Correlation & Price change

A.I.dvisor tells us that AQST and ETON have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AQST and ETON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+1.14%
ETON - AQST
31%
Poorly correlated
-3.83%
NBIX - AQST
29%
Poorly correlated
-0.38%
TLRY - AQST
28%
Poorly correlated
+6.52%
ESPR - AQST
27%
Poorly correlated
+3.08%
ACET - AQST
26%
Poorly correlated
+2.08%
More

Groups containing AQST

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+1.14%
Pharmaceuticals: Generic
industry (214 stocks)
37%
Loosely correlated
+0.29%